<DOC>
	<DOCNO>NCT00442910</DOCNO>
	<brief_summary>There urgent need HIV prevention method woman initiate control . Topical microbicides , substance kill microbe , represent one method . The purpose study assess safety evaluate acceptability 3 % w/w SPL7013 gel , topical microbicide , administer intravaginally 14 consecutive day healthy , sexually active HIV uninfected woman .</brief_summary>
	<brief_title>Safety Acceptability SPL7013 Gel ( VivaGelâ„¢ ) Sexually Active Women</brief_title>
	<detailed_description>Women continue comprise grow proportion new HIV infection around world . A grow body data suggest safe effective topical microbicide real option prevention woman future . The purpose study assess safety acceptability 3 % SPL7013 Gel administer intravaginally , twice daily 14 consecutive day healthy , sexually-active , HIV-uninfected woman . The expected duration study participant 21 day . Study participant randomly assign one two arm . Participants Arm 1 apply 3.5 g SPL7013 gel intravaginally twice daily 14 consecutive day . Participants Arm 2 apply placebo gel intravaginally twice daily 14 consecutive day . Starpharma produce SPL7013 gel ( VivaGel ) provide study . After enrollment , participant attend three study visit . These visit occur Days 7 , 14 , 21 . A follow-up safety visit occur necessary . Medical menstrual history , target physical exam , urine blood collection , cervical swab , vaginal smear occur visit . A colposcopy occur least . On Day 2 , participant take part phone assessment .</detailed_description>
	<criteria>HIVuninfected General good health Normal Pap result within 12 month prior study entry Predictable menstrual cycle least 21 day menses Sexually active Willing use effective method contraception duration study . More information criterion find protocol . Willing abstain oralvaginal penileanal intercourse duration study Willing use intravaginal product and/or device 72 hour prior study entry Week 3 Agree partner use condom provide study act intercourse study participation Willing undergo colposcopy determine necessary investigator Agree participate drug device study study participation History adverse reaction latex component study product History male sex partner allergic reaction latex Any abnormal finding physical pelvic examination Sexually transmit infection ( STI ) reproductive tract infection . More information criterion available protocol . Diagnosed STI within 6 month prior study entry Use oral and/or vaginal preparation antibiotic antifungal medication within 30 day prior study entry Gynecological surgical procedure within 90 day prior study entry Certain abnormal laboratory value . More information criterion available protocol . Received nontherapeutic intravenous drug within 12 month prior study entry Any social medical condition , , opinion investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Safety Acceptability</keyword>
</DOC>